News Focus
News Focus
Followers 51
Posts 2240
Boards Moderated 0
Alias Born 07/06/2011

Re: Hugon post# 357220

Wednesday, 04/28/2021 10:41:27 AM

Wednesday, April 28, 2021 10:41:27 AM

Post# of 405172
Agree, we need updates on everything.
Everything seems to be on hold or making very slow progress, which is what you get for our shoestring budget and lack of capital.

I was somehow expecting some interim analysis for efficacy, based on prior guidance, and was thinking the 50% number would be it. I guess that's not happening. We only got the interim safety analysis to permit increased dosing from 3 to 5 days (after 25%).

Maybe it was this 10/20/20 PR:

http://www.ipharminc.com/press-release/2020/10/2/innovation-pharmaceuticals-announces-pre-ind-meeting-request-granted-by-fda-for-the-study-of-brilacidin-for-the-treatment-of-covid-19

Target enrollment is 120 patients, with a planned interim analysis.



Guess this was interim safety, not efficacy.

I thought there was something else, but can't find it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y